ClinicalTrials.gg
TerminatedNCT04866017Updated Oct 31, 2024Results posted

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

A Phase 3 interventional study of Tislelizumab and Durvalumab in Non Small Cell Lung Cancer, sponsored by BeiGene. Terminated at 35 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Why this study was terminated
This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the ociperlimab program.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 22 under way, 2 of them phase 3. tislelizumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 41
63 · median 39
Started
2021
with 4 others
Phase 3
9 of 41
none open now
Registered
8th of 41
by date
Lead sponsor
10 of 41
BeiGene

Among the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is one of 5 that started in 2021, is one of 9 in phase 3, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About tislelizumab

tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing tislelizumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the safety and efficacy of ociperlimab in combination with tislelizumab compared to durvalumab in adults with stage III unresectable PD-L1-selected non-small cell lung cancer whose disease has not progressed after cCRT.

Read the detailed description

The study initiated with Protocol Amendment 1.0 (PA 1; dated on 16 April 2021). In April 2022 Protocol Amendment 2 (PA 2) was implemented. In PA 1, participants with newly diagnosed, histologically confirmed, unresectable locally advanced NSCLC and evaluable PD-L1 expression all comers were enrolled; cCRT was given within the study. In PA 2, the enrollment of the target population was revised into participants with unresectable locally advanced NSCLC whose disease has not progressed after definitive, platinum-based cCRT and with PD-L1 expression on ≥ 1% of tumor cells as assessed by the central lab; cCRT was given outside of the study.

After implementation of PA 2, participants who were randomized under PA 1 were given the option to continue assigned study treatment or to discontinue assigned treatment and begin standard of care treatment outside of the study. Participants enrolled under PA 1 were excluded from the primary and secondary analysis specified by PA 2.

This study was subsequently terminated by the Sponsor prior to enrollment of any participants under PA 2.

03

Conditions studied

  • Non Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Age ≥ 18 years on the day of signing the form (or the legal age of consent in the jurisdiction in which the study is taking place).
  2. Participant has or cytologically confirmed, locally advanced, unresectable Stage III NSCLC (AJCC Cancer Staging Manual 2017, derived from IASLC) prior to initiation of cCRT.
  3. Participant must have completed at least 2 cycles of platinum-based chemotherapy concurrent with radiotherapy
  4. Participants must have not experienced PD following definitive, platinum-based cCRT.
  5. Eastern Co-operative Oncology Group () Performance Status of 0 or 1.
  6. Participants must have adequate organ function
  7. Agree to provide (formalin-fixed paraffin-embedded block containing tumor [preferred] or approximately 6 to 15 freshly cut unstained slides) or fresh biopsy obtained prior to cCRT (if archival tissue is not available) for prospective central evaluation of levels and retrospective analysis of other biomarkers.

Key Exclusion Criteria:

  1. Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, TIGIT, or any other antibody or drugs specifically targeting T-cell co-stimulation or checkpoint pathways.
  2. Diagnosed with NSCLC that harbors an epidermal growth factor receptor (EGFR) sensitizing mutation, anaplastic lymphoma kinase (ALK) gene translocation, ROS1 gene translocation or RET gene rearrangement.
  3. Participants who received systemic anticancer treatment besides the specified cCRT.
  4. Any unresolved toxicity > Grade 2 from the prior cCRT.
  5. Active diseases or history of autoimmune diseases that may relapse.
  6. Any condition that required systemic treatment with either (> 10 mg daily of prednisone [in Japan, prednisolone] or equivalent) or other medication ≤ 14 days before the first dose of study treatment.
  7. Infection (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal, or antiviral therapy within 14 days before the first dose of study treatment.

Note: Antiviral therapy is permitted for participants with chronic virus (HBV) or virus (HCV) infection.

NOTE: Other protocol Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Ociperlimab + Tislelizumab + cCRT

    Participants enrolled under PA1 recieved two cycles of ociperlimab combined with tislelizumab and cCRT, followed by ociperlimab combined with tislelizumab up to 1 year after the cCRT phase

    Drug: Tislelizumab · Drug: Ociperlimab · Drug: Chemotherapy · Radiation: Radiotherapy

  • Experimental
    Tislelizumab + cCRT

    Participants enrolled under PA1 recieved two cycles of tislelizumab combined with cCRT, followed by tislelizumab up to 1 year after the cCRT phase

    Drug: Tislelizumab · Drug: Chemotherapy · Radiation: Radiotherapy

  • Experimental
    cCRT followed by Durvalumab

    Participants enrolled under PA1 recieved two cycles of cCRT, followed by durvalumab to 1 year after the cCRT phase

    Drug: Durvalumab · Drug: Chemotherapy · Radiation: Radiotherapy

Interventions

  • 200 mg intravenously every three weeks

    Also known as: BGB-A317

  • 10 milligrams per kilogram (mg/kg) intravenously once every 2 weeks (or 1500 mg intravenously once every 4 weeks where the dosage has been approved by a local health authority)

  • 900 milligrams (mg) intravenously every three weeks

    Also known as: BGB-A1217

  • DrugChemotherapy

    The chemotherapy regimen for the study treatment was selected at the investigator's discretion and may include one of the following options: * Cisplatin (50 mg/m²) on days 1 to 5 of each cycle, combined with etoposide (50 mg/m²) on days 1 and 8, both administered intravenously for 2 cycles. Each cycle was 28 days. * Carboplatin (AUC 2) weekly for 6 weeks, combined with paclitaxel (40-50 mg/m²) weekly for 6 weeks, both administered intravenously. * Cisplatin (75 mg/m²) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. * Carboplatin (AUC 5) combined with pemetrexed (500 mg/m²) on day 1 of each cycle, administered intravenously for 2 cycles. Each cycle was 21 days. The pemetrexed plus platinum regimen was only for participants with non-squamous histology.

    Also known as: Concurrent Chemoradiotherapy (cCRT)

  • RadiationRadiotherapy

    All participants recieved radiotherapy using either a standardized 3-dimensional conformal radiotherapy technique, or intensity modulated radiotherapy (IMRT) on a linear accelerator delivering a beam energy of ≥ 6 MV. The total dose of radiotherapy was 60 Gy, administered in 30 once-daily fractions of 2 Gy and 5 fractions per week for 6 weeks.

    Also known as: Concurrent Chemoradiotherapy (cCRT)

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

    PFS is defined as the time from the date of randomization to the date of first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death, whichever occurred first.

    Time frame: From randomization through to the end of study, planned duration was 20 months

Secondary outcomes

  1. Overall Survival (OS)

    Defined as the time from the date of randomization until the date of death due to any cause

    Time frame: From randomization through to the end of study, planned duration was 20 months

  2. Overall Response Rate (ORR)

    Defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) assessed by both the IRC and investigators per RECIST v1.1.

    Time frame: From randomization through to the end of study, planned duration was 20 months

  3. Duration of Response (DOR)

    defined as the time from the first determination of a confirmed objective response assessed by both the IRC and investigators per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first

    Time frame: From randomization through to the end of study, planned duration was 20 months

  4. Time to Death or Distant Metastasis (TTDM) as Assessed by the Investigator

    defined as the time from the date of randomization until the first date of distant metastasis assessed by both the IRC and investigators, or death. Distant metastasis is defined as any new lesion that is outside of the radiation field per RECIST v1.1 or proven by biopsy.

    Time frame: From randomization through to the end of study, planned duration was 20 months

  5. Progression-Free Survival 2 (PFS2)

    defined as the time from randomization to the disease progression after next line of treatment, or death from any cause, whichever occurs first

    Time frame: From randomization through to the end of study, planned duration was 20 months

  6. Number of Participants Experiencing Adverse Events (AEs)

    Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)

    Time frame: From first dose to 30 days after the last dose or initiation of a new anticancer therapy, whichever occured first; through study completion data cut-off date of October 17th, 2023 (maximum time on treatment was 16 months)

  7. Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

    Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

    Time frame: Baseline and Cycle 6 (Each cycle is 21 days)

  8. Change From Baseline in Health Related Quality of Life (HRQoL) as Assessed by Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)

    Change from baseline in QLQ-CL13 scores for coughing, dyspnea, and chest pain. The QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.

    Time frame: Baseline and Cycle 6 (Each cycle is 21 days)

  9. Change From Baseline in Health Related Quality of Life (HRQoL) as Assessed by European Quality of Life-5 Dimensions (EQ-5D-5L)

    The EuroQol 5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.

    Time frame: Baseline and Cycle 6 (Each cycle is 21 days)

  10. Serum Concentration of Ociperlimab

    Serum concentrations of ociperlimab were measured for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date the investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.

    Time frame: Predose at Day 1 of Cycles 1, 2, 5, 9, and 17; postdose on Day 1 of Cycles 1, 5 and EOT visit (Each Cycle was 21 days)

  11. Serum Concentration of Tislelizumab for Participants in the Ociperlimab + Tislelizumab + cCRT Treatment Group

    Serum concentrations of tislelizumab were collected for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.

    Time frame: Predose at Day 1 of Cycles 1, 2, 5, 9, 17; postdose on Day 1 of Cycles 1 and 5, and EOT visit (each cycle was 21 days)

  12. Serum Concentration of Tislelizumab for Participants in the Tislelizumab + cCRT Treatment Group

    Serum concentrations of tislelizumab were collected for participants in the Tislelizumab + cCRT treatment group at predose (within 60 minutes prior to infusion initiation) and postdose (within 30 minutes after the completion of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.

    Time frame: Predose at Day 1 of Cycles 1, 2, 5, 9, and 17; postdose on Day 1 of Cycles 1 and 5, and EOT visit (Each Cycle is 21 days)

  13. Immunogenic Responses to Ociperlimab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)

    Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (ociperlimab and tislelizumab)

    Time frame: Predose (within 60 minutes before dose) on Day 1 of Cycles 1, 2, 5, 9, 17, and the EOT Visit (Each cycle is 21 days). Maximum number of treatment cycles was 19

  14. Immunogenic Responses to Tislelizumab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)

    Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (Ociperlimab + Tislelizumab + cCRT) and Arm B (Tislelizumab + cCRT)

    Time frame: Predose (within 60 minutes before dose) on Day 1 of Cycles 1, 2, 5, 9, 17, and the EOT Visit (Each cycle is 21 days, maximum number of treatment cycles was 19)

  15. Programmed Death-Ligand 1 (PD-L1) and T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Expression in Archival and/or Fresh Tumor Tissues

    Time frame: From randomization through to the end of study, planned duration was 20 months

07

Results

Posted Oct 31, 2024
Limitations and caveats
Since no participants were enrolled under PA 2, no analyses of the primary or secondary endpoints were conducted. Participants enrolled under PA 1 were excluded from the primary and secondary analyses outlined for PA 2.

Participant flow

Participants were enrolled in multiple study centers in Taiwan, China, Spain , United States, and Australia. The first participant was consented on June 17th, 2021, and the last participant completed on October 17th, 2023. The decision to terminate the study was made on July 11th, 2023.

Participant flow — Overall Study
MilestoneOciperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by Durvalumab
Started221922
Treated221822
Completed000
Not completed221922
Withdrew: Study terminated by sponsor131413
Withdrew: Death848
Withdrew: Withdrawal by subject101
Withdrew: Physician decision010

Outcome measures

PrimaryProgression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

PFS is defined as the time from the date of randomization to the date of first documentation of disease progression as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 or death, whichever occurred first.

Time frame:
From randomization through to the end of study, planned duration was 20 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Defined as the time from the date of randomization until the date of death due to any cause

Time frame:
From randomization through to the end of study, planned duration was 20 months

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR)

Defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) assessed by both the IRC and investigators per RECIST v1.1.

Time frame:
From randomization through to the end of study, planned duration was 20 months

No measurements were reported for this outcome.

SecondaryDuration of Response (DOR)

defined as the time from the first determination of a confirmed objective response assessed by both the IRC and investigators per RECIST v1.1 until the first documentation of disease progression or death, whichever occurs first

Time frame:
From randomization through to the end of study, planned duration was 20 months

No measurements were reported for this outcome.

SecondaryTime to Death or Distant Metastasis (TTDM) as Assessed by the Investigator

defined as the time from the date of randomization until the first date of distant metastasis assessed by both the IRC and investigators, or death. Distant metastasis is defined as any new lesion that is outside of the radiation field per RECIST v1.1 or proven by biopsy.

Time frame:
From randomization through to the end of study, planned duration was 20 months

No measurements were reported for this outcome.

SecondaryProgression-Free Survival 2 (PFS2)

defined as the time from randomization to the disease progression after next line of treatment, or death from any cause, whichever occurs first

Time frame:
From randomization through to the end of study, planned duration was 20 months

No measurements were reported for this outcome.

SecondaryNumber of Participants Experiencing Adverse Events (AEs)

Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) determined according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)

Time frame:
From first dose to 30 days after the last dose or initiation of a new anticancer therapy, whichever occured first; through study completion data cut-off date of October 17th, 2023 (maximum time on treatment was 16 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events (AEs)
ParticipantsOciperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by Durvalumab
TEAEs221822
SAEs1188
SecondaryChange From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status

Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.

Time frame:
Baseline and Cycle 6 (Each cycle is 21 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline in Health Related Quality of Life (HRQoL) as Assessed by Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)

Change from baseline in QLQ-CL13 scores for coughing, dyspnea, and chest pain. The QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is "not at all" and 4 is "very much". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.

Time frame:
Baseline and Cycle 6 (Each cycle is 21 days)

No measurements were reported for this outcome.

SecondaryChange From Baseline in Health Related Quality of Life (HRQoL) as Assessed by European Quality of Life-5 Dimensions (EQ-5D-5L)

The EuroQol 5D-5L a descriptive system that comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The participant is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the participant's health state.

Time frame:
Baseline and Cycle 6 (Each cycle is 21 days)

No measurements were reported for this outcome.

SecondarySerum Concentration of Ociperlimab

Serum concentrations of ociperlimab were measured for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date the investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.

Time frame:
Predose at Day 1 of Cycles 1, 2, 5, 9, and 17; postdose on Day 1 of Cycles 1, 5 and EOT visit (Each Cycle was 21 days)
Reported as:
Geometric mean · ug/ml
Serum Concentration of Ociperlimab
ug/mlOciperlimab + Tislelizumab + cCRT: PredoseOciperlimab + Tislelizumab + cCRT: Postdose
Cycle 1 Day 118 ± NA312 ± 45.82
Cycle 2 Day 134.54 ± 63.19—
Cycle 5 Day 174.86 ± 61.76339.31 ± 38.21
Cycle 9 Day 152.4 ± 82.40—
Cycle 17 Day 181.35 ± 53.83—
End of Treatment—94.94 ± 232.05
SecondarySerum Concentration of Tislelizumab for Participants in the Ociperlimab + Tislelizumab + cCRT Treatment Group

Serum concentrations of tislelizumab were collected for participants in the Ociperlimab + Tislelizumab + cCRT treatment group at predose (within 60 minutes before starting infusion) and postdose (within 30 minutes after the end of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.

Time frame:
Predose at Day 1 of Cycles 1, 2, 5, 9, 17; postdose on Day 1 of Cycles 1 and 5, and EOT visit (each cycle was 21 days)
Reported as:
Geometric mean · ug/mL
Serum Concentration of Tislelizumab for Participants in the Ociperlimab + Tislelizumab + cCRT Treatment Group
ug/mLOciperlimab + Tislelizumab + cCRT: PredoseOciperlimab + Tislelizumab + cCRT: Postdose
Cycle 1 Day 1NA ± NA72.20 ± 26.27
Cycle 2 Day 115.91 ± 78.83—
Cycle 5 Day 134.10 ± 49.6797.08 ± 23.09
Cycle 9 Day 130.22 ± 55.34—
Cycle 17 Day 132.24 ± 156.53—
End of Treatment—49.55 ± 89.19
SecondarySerum Concentration of Tislelizumab for Participants in the Tislelizumab + cCRT Treatment Group

Serum concentrations of tislelizumab were collected for participants in the Tislelizumab + cCRT treatment group at predose (within 60 minutes prior to infusion initiation) and postdose (within 30 minutes after the completion of infusion). End of Treatment (EOT) visits occurred within 7 days after the date investigator determined that study treatment would no longer be used, or before the initiation of a new anticancer treatment, whichever occurred first.

Time frame:
Predose at Day 1 of Cycles 1, 2, 5, 9, and 17; postdose on Day 1 of Cycles 1 and 5, and EOT visit (Each Cycle is 21 days)
Reported as:
Geometric mean · ug/mL
Serum Concentration of Tislelizumab for Participants in the Tislelizumab + cCRT Treatment Group
ug/mLTislelizumab: PredoseTislelizumab: Postdose
Cycle 1 Day 1NA ± NA73.41 ± 18.53
Cycle 2 Day 119.69 ± 27.01—
Cycle 5 Day 137.64 ± 47.00100.26 ± 29.25
Cycle 9 Day 136.98 ± 39.63—
Cycle 17 Day 141.29 ± 55.41—
End of Treatment—40.18 ± 139.51
SecondaryImmunogenic Responses to Ociperlimab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)

Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (ociperlimab and tislelizumab)

Time frame:
Predose (within 60 minutes before dose) on Day 1 of Cycles 1, 2, 5, 9, 17, and the EOT Visit (Each cycle is 21 days). Maximum number of treatment cycles was 19
Reported as:
Count of participants · Participants
Immunogenic Responses to Ociperlimab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)
ParticipantsOciperlimab + Tislelizumab + cCRT
Immunogenic Responses to Ociperlimab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)0
SecondaryImmunogenic Responses to Tislelizumab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)

Defined as the sum of treatment-boosted and treatment-induced ADA participants as a proportion percentage of the ADA-evaluable participants population and is synonymous with 'ADA Incidence'. ADA samples were collected for participants randomized to Arm A (Ociperlimab + Tislelizumab + cCRT) and Arm B (Tislelizumab + cCRT)

Time frame:
Predose (within 60 minutes before dose) on Day 1 of Cycles 1, 2, 5, 9, 17, and the EOT Visit (Each cycle is 21 days, maximum number of treatment cycles was 19)
Reported as:
Count of participants · Participants
Immunogenic Responses to Tislelizumab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)
ParticipantsOciperlimab + Tislelizumab + cCRTTislelizumab + cCRT
Immunogenic Responses to Tislelizumab as Assessed by the Detection of Treatment Emergent Anti-Drug Antibodies (ADAs)105
SecondaryProgrammed Death-Ligand 1 (PD-L1) and T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Expression in Archival and/or Fresh Tumor Tissues
Time frame:
From randomization through to the end of study, planned duration was 20 months

No measurements were reported for this outcome.

Adverse events

Collected over From first dose to 30 days after the last dose or initiation of a new anticancer therapy, whichever occured first; through study completion data cut-off date of October 17th, 2023 (maximum time on treatment was 16 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ociperlimab + Tislelizumab + cCRT8/22 (36.4%)11/22 (50%)22/22 (100%)
Tislelizumab + cCRT4/18 (22.2%)8/18 (44.4%)18/18 (100%)
cCRT Followed by Durvalumab8/22 (36.4%)8/22 (36.4%)22/22 (100%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventOciperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by Durvalumab
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders3/222/180/22
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders2/222/180/22
PneumoniaInfections and infestations2/221/181/22
HaemoptysisRespiratory, thoracic and mediastinal disorders0/221/182/22
PneumonitisRespiratory, thoracic and mediastinal disorders2/220/180/22
Lower respiratory tract infectionInfections and infestations0/221/180/22
SinusitisInfections and infestations0/221/180/22
Radiation pneumonitisInjury, poisoning and procedural complications1/221/180/22
HyponatraemiaMetabolism and nutrition disorders0/221/180/22
Type 1 diabetes mellitusMetabolism and nutrition disorders0/221/180/22
Most frequent other events
Showing 10 of 212
Most frequent other events
EventOciperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by Durvalumab
White blood cell count decreasedInvestigations15/2210/1813/22
AnaemiaBlood and lymphatic system disorders12/2210/1814/22
Neutrophil count decreasedInvestigations14/225/1813/22
NauseaGastrointestinal disorders6/227/1811/22
Platelet count decreasedInvestigations8/225/1810/22
ConstipationGastrointestinal disorders9/225/188/22
Radiation oesophagitisInjury, poisoning and procedural complications6/223/189/22
Alanine aminotransferase increasedInvestigations8/220/186/22
HypoalbuminaemiaMetabolism and nutrition disorders5/226/187/22
Decreased appetiteMetabolism and nutrition disorders7/225/187/22

Baseline characteristics

The Intent-to-Treat (ITT) Analysis Set is defined as all randomized participants.

Age, Continuous
Age, Continuous(years)Ociperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by DurvalumabTotal
Mean63.4 ± 7.5162.4 ± 9.2764.1 ± 7.3663.3 ± 7.93
Sex: Female, Male
Sex: Female, Male(Participants)Ociperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by DurvalumabTotal
Female3508
Male19142255
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Ociperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by DurvalumabTotal
American Indian or Alaska Native1001
Asian18151851
White44412
Region of Enrollment
Region of Enrollment(participants)Ociperlimab + Tislelizumab + cCRTTislelizumab + cCRTcCRT Followed by DurvalumabTotal
China17121645
Taiwan1326
Spain1135
United States2114
Australia1203
08

Study locations

35 sites
  • XCancer/Centeral Care Center
    Bolivar, Missouri 65613, United States
  • Southern Medical Day Care Centre
    Wollongong, New South Wales NSW 2500, Australia
  • Townsville Hospital
    Douglas, Queensland 4814, Australia
  • Lyell McEwin Hospital
    Elizabeth Vale, South Australia 5112, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania, Australia
  • Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Gold Coast University Hospital
    Gold Coast, 4215, Australia
  • Hollywood Private Hospital
    Perth, Australia
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Chongqing University Cancer Hospital
    Chongqing, Chongqing 400030, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, Guangdong, China
  • Hunan Cancer Hospital - GCP Office
    Changsha, Hunan 410013, China
  • Nanjing First Hospital
    Nanjing, Jiangsu 210009, China
  • The First Affiliated Hospital of Soochow University Branch Shizi
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital of Nanchang University Branch Donghu
    Nanchang, Jiangxi 330006, China
  • Jilin Cancer Hospital
    Changchun, Jilin 130021, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Shandong Cancer Hospital and Institute, Shandong First Medical University
    Jinan, Shandong 250117, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, Tianjin 300060, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Peking University Third Hospital
    Beijing, China
  • Changzhou Cancer Hospital
    Changzhou, 213000, China
  • Jieyang People'S Hospital (Jieyang Affiliated Hospital, Sun Yat-Sen University )
    Jieyang, 522091, China
  • Hospital Universitario Fundación Jiménez Díaz
    Alcorcon, Madrid 28040, Spain
  • Instituto Oncologico Dr. Rosell
    Barcelona, 08028, Spain
  • Ico Girona
    Girona, 17007, Spain
  • Changhua Christian Hospital
    Changhua, 50006, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 40201, Taiwan
  • Taichung Veterans General Hospital
    Taichung, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Oct 2023, 28 months.

Results were first posted in Oct 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2020
First posted
Apr 29, 2021
StartActual
Jun 17, 2021
Primary completionActual
Oct 17, 2023
CompletionActual
Oct 17, 2023
Results first posted
Oct 31, 2024
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04866017
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Jun 17, 2021
Primary completion
Oct 17, 2023
Completion
Oct 17, 2023
Results posted
Oct 31, 2024
Last update
Oct 31, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tislelizumab · Ociperlimab

Start the discussion